0 items USD 0.00Therapeutics Pipeline Landscape of Coronavirus Disease 2019 (COVID-19)
The global Coronavirus Mortality Rate is 4.3%. In the 5MM, the highest case fatality rate occurs among the 80 years and older age group. In the 5MM (except Spain), the highest proportion of deaths occurs among the 80 years and older age group.
People at risk for severe COVID-19 include population with underlying health problems, such as respiratory disease, cardiovascular disease, cancer, diabetes, and some rare diseases. Populations aged 50 years of age and older are also more likely to have comorbidities and develop severe COVID-19, requiring hospitalization. There is no solid evidence to suggest that pregnant women are more at risk of COVID-19, but they are included in this category as a precaution.
In rare instances, coronavirus variants have been known to cause severe disease in humans. There are three such cases: severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.
The COVID-19 therapeutic pipeline consists of 89 drugs spanning all stages of development (discovery to Phase III); 16 of these drugs have reached clinical-stage development, Phases I–III. The pipeline is largely in the early stage, with approximately 69% of the drugs in discovery and preclinical phases. The lack of a vaccine means that the outbreak has spread nearly unabated, slowed only by such prevention measures as social distancing without the benefit of any vaccine-conferred immunity in the population.
For patients diagnosed with COVID-19, the unavailability of any treatments proven to be efficacious in relieving symptoms, and treating the underlying disease means that supportive care is the only therapeutic option.
Related COVID-19 Pipeline Reports
Related Industry Articles
1. Covid-19 Impact on Global Economy: Analysis of Major Industries
2. COVID-19 Impact: Forecasts of Products and Services that are Directly Affected by the Pandemic
3. Covid-19 Impact on Global Ventilator Market
Email a colleague
Printer version
Send by email
About The Author
